Drug intelligence / Profile preview

KMHH-03

Development stage: Unknown
Lead developer: Beijing Kangming Hanghui Biotechnology
Administration: Injectable

Overview

KMHH-03 is an investigational drug currently being studied as an injectable therapy for advanced breast cancer. The primary objectives of ongoing clinical trials are to evaluate the safety, tolerability, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of single-dose administration in patients with advanced breast cancer. Secondary objectives include assessment of pharmacokinetic characteristics, immunogenicity, and preliminary efficacy to inform future dosing regimens and trial design. The drug is being developed by Beijing Kangming Hanghui Biotechnology[1].

Beyond the preview

Go deeper on KMHH-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KMHH-03.

Explore the full profile